Journal
INTERNATIONAL JOURNAL OF NANOMEDICINE
Volume 8, Issue -, Pages 3309-3319Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S38354
Keywords
liposome; platinum analog; drug delivery; cancer
Funding
- NCI NIH HHS [R01 CA178748] Funding Source: Medline
Ask authors/readers for more resources
Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further. Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin (TM)), SPI-77, Lipoplatin (TM), Lipoxal (TM), and LiPlaCis (R). Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles. We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available